Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin
May 4, 2022
Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...
May 3, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Multi-modal PET drives interdisciplinary preclinical imaging
Feb 23, 2022
Preclinical imaging (PCI) plays a vital role in understanding the biological processes behind disease states at the...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Reduces fMRI-BOLD Response in the Brain
Feb 18, 2022
fMRI studies often involve the electrical stimulation of i.e. the forepaw, detecting where this stimulation is...
Oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer at a single low dose
Oct 24, 2019
Trough this study we have seen that CF33 and CF33-Fluc are safe and efective in vitro and in vivo. Trough chimerization and high throughput screening, the novel virus have been created that requires lower doses to treat pancreatic cancer in a preclinical model. CF33-Fluc replication in non-injected, distant tumors halted tumor growth. Further studies in immune-competent models investigating the mechanisms of rapid tumor regression and viral spread to non-injected tumors following a low viral dose will enhance our understanding of how this novel virus targets and kills pancreatic cancer.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
